Factors associated with inflammation markers, a cross-sectional analysis

Cytokine

Volumn 56, Issue 3, 2011, Pages 769-778

  Clendenen, Tess V ^a   Koenig, Karen L ^a   Arslan, Alan A ^a   Lukanova, Annekatrin ^a,b   Berrino, Franco ^c   Gu, Yian ^a   Hallmans, Goran ^d   Idahl, Annika ^d   Krogh, Vittorio ^c   Lokshin, Anna E ^e,f,g   Lundin, Eva ^d   Muti, Paola ^h   Marrangoni, Adele ^e   Nolen, Brian M ^e   Ohlson, Nina ^d   Shore, Roy E ^a,i   Sieri, Sabina ^c   Zeleniuch Jacquotte, Anne ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UMEÅ UNIVERSITY   (Sweden)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

ⁱ RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

Author keywords

C reactive protein; Cross sectional studies; Cytokine receptors; Cytokines; Epidemiologic factors

Indexed keywords

25 HYDROXYVITAMIN D; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR A; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; SOLUBLE INTERLEUKIN 2 RECEPTOR; SOLUBLE INTERLEUKIN 2 RECEPTOR A; SOLUBLE INTERLEUKIN 4 RECEPTOR; SOLUBLE INTERLEUKIN 6 RECEPTOR; SOLUBLE INTERLEUKIN RECEPTOR; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CHRONIC DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG USE; FAMILY HISTORY; FEMALE; HUMAN; INFLAMMATION; LIFESTYLE; OVARY CANCER; PARITY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; RISK FACTOR; SMOKING; WOMEN'S HEALTH;

ADULT; AGED; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS;

EID: 81455131451     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.09.013     Document Type: Article

References (74)

1. Kushner I., Rzewnicki D., Samols D. What does minor elevation of C-reactive protein signify?. Am J Med 2006, 119(2):17-28.
2. Pradhan A.D., et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286(3):327-334.
3. Ridker P.M., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101(15):1767-1772.
4. Siemes C., et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk the Rotterdam study. J Clin Oncol 2006, 24(33):5216-5222.
5. Il'yasova D., et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidem Biomar 2005, 14(10):2413-2418.
6. Chaturvedi A.K., et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010, 28(16):2719-2726.
7. Tsilidis K.K., et al. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 2008, 123(5):1133-1140.
8. Aleksandrova K., et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European prospective investigation into cancer and nutrition. Am J Epidemiol 2010, 172(4):407-418.
9. McSorley M.A., et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 2007, 109(4):933-941.
10. Clendenen T.V., et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidem Biomar 2011, 20(5):799-810.
11. Gu Y., et al. Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study. Cancer Cause Control 2010, 21(8):1323-1333.
12. Saberi Hosnijeh F., et al. Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European prospective investigation into cancer and nutrition. Cancer Epidem Biomar 2010, 19(6):1577-1584.
13. Purdue M.P., et al. Prediagnostic serum levels of cytokines and other immune markers and risk of non-Hodgkin lymphoma. Cancer Res 2011, 71(14):4898-4907.
14. Danesh J., et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008, 5(4):e78.
15. Yamagishi S., et al. Decreased high-density lipoprotein cholesterol level is an independent correlate of circulating tumor necrosis factor-alpha in a general population. Clin Cardiol 2009, 32(9):E29-E32.
16. Cantorna M.T., et al. Vitamin D status, 1, 25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004, 80(6 Suppl.):17S-20S.
17. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrin Metab Clin 2010, 39(2):365-379.
18. Wong H.L., et al. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidem Biomar 2008, 17(12):3450-3456.
19. Gu Y., et al. Reproducibility of serum cytokines and growth factors. Cytokine 2009, 45(1):44-49.
20. Clendenen T.V., et al. Temporal reliability of cytokines and growth factors in EDTA plasma. BMC Res Notes 2010, 3:302-310.
21. Toniolo P.G., et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995, 87(3):190-197.
22. Toniolo P.G., et al. Endogenous hormones and breast cancer: a prospective cohort study. Breast Cancer Res Treat 1991, 18(Suppl. 1):S23-S26.
23. Hallmans G., et al. Cardiovascular disease and diabetes in the Northern Sweden health and disease study Cohort-evaluation of risk factors and their interactions. Scand J Public Health 2003, 61(Suppl. 1):18-24.
24. Berrino F., et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996, 88(5):291-296.
25. Non-steroidal anti-inflammatory drugs (NSAIDs) - clinical effect and indication. In: Rovenský J, Payer J, editors. Dictionary of rheumatology. Vienna: Springer; 2009. p. 145-6.
26. Vignali D.A. Multiplexed particle-based flow cytometric assays. J Immunol Meth 2000, 243(1-2):243-255.
27. Zheng W., et al. Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010, 172(1):70-80.
28. Purdue M.P., et al. Circulating 25-hydroxyvitamin D and risk of non-hodgkin lymphoma: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010, 172(1):58-69.
29. Arslan A.A., et al. Circulating vitamin d and risk of epithelial ovarian cancer. J Oncol 2009, 2009:672492.
30. Lubin J.H., et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Persp 2004, 112(17):1691-1696.
31. Sites C.K., et al. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 2002, 77(1):128-135.
32. Hong S.C., et al. Correlation between estrogens and serum adipocytokines in premenopausal and postmenopausal women. Menopause 2007, 14(5):835-840.
33. Kamada M., et al. Postmenopausal changes in serum cytokine levels and hormone replacement therapy. Am J Obstet Gynecol 2001, 184(3):309-314.
34. Welsh P., et al. Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow Monica study. Br J Haematol 2008, 141(6):852-861.
35. Yasui T., et al. Changes in serum cytokine concentrations during the menopausal transition. Maturitas 2007, 56(4):396-403.
36. Cioffi M., et al. Cytokine pattern in postmenopause. Maturitas 2002, 41(3):187-192.
37. Asztalos S., et al. Gene expression patterns in the human breast after pregnancy. Cancer Prev Res (Phila) 2010, 3(3):301-311.
38. Ikonomidis I., et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999, 100(8):793-798.
39. Feng D., et al. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolys 2000, 9(1):37-41.
40. Feldman M., et al. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001, 37(8):2036-2041.
41. Kim S., et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008, 68(1):323-328.
42. Azar R.R., et al. Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. Am J Cardiol 2003, 92(2):236-239.
43. Ho G.Y., et al. Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. J Natl Cancer Inst 2009, 101(23):1650-1654.
44. Bermudez E.A., et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscl Thromb Vas 2002, 22(10):1668-1673.
45. Danesh J., et al. Risk factors for coronary heart disease and acute-phase proteins. a population-based study. Eur Heart J 1999, 20(13):954-959.
46. Bazzano L.A., et al. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003, 138(11):891-897.
47. Levitzky Y.S., et al. Relation of smoking status to a panel of inflammatory markers: the framingham offspring. Atherosclerosis 2008, 201(1):217-224.
48. Noakes P.S., Holt P.G., Prescott S.L. Maternal smoking in pregnancy alters neonatal cytokine responses. Allergy 2003, 58(10):1053-1058.
49. Cozen W., et al. Th1 and Th2 cytokines and IgE levels in identical twins with varying levels of cigarette consumption. J Clin Immunol 2004, 24(6):617-622.
50. Pine S.R., et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 2011, 103(14):1112-1122.
51. Tsunoda M., et al. Serum cytokine levels, cigarette smoking and airway responsiveness among pregnant women. Int Arch Allergy Imm 2003, 130(2):158-164.
52. Jorde R., et al. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 2010, 50(2):175-180.
53. Frohlich M., et al. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (Monica Augsburg survey 1994/95). Eur Heart J 2003, 24(14):1365-1372.
54. Tracy R.P., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vas 1997, 17(10):2167-2176.
55. Ahonen T.M., et al. Gender difference among smoking, adiponectin, and high-sensitivity C-reactive protein. Am J Prev Med 2008, 35(6):598-601.
56. Spranger J., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-potsdam study. Diabetes 2003, 52(3):812-817.
57. Hu F.B., et al. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004, 53(3):693-700.
58. Ridker P.M., et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999, 100(7):713-716.
59. Pantsulaia I., et al. Genetic and environmental influences on IL-6 and TNF-alpha plasma levels in apparently healthy general population. Cytokine 2002, 19(3):138-146.
60. Yasui T., et al. Associations of interleukin-6 with interleukin-1beta, interleukin-8 and macrophage inflammatory protein-1beta in midlife women. Cytokine 2008, 41(3):302-306.
61. Heaney M.L., Golde D.W. Soluble receptors in human disease. J Leukocyte Biol 1998, 64(2):135-146.
62. Jung T., et al. Enhancement of human IL-4 activity by soluble IL-4 receptors in vitro. Eur J Immunol 1999, 29(3):864-871.
63. Mitsuyama K., et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995, 36(1):45-49.
64. Kovacs E. Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed Pharmacother 2001, 55(7):391-396.
65. Peterson C.A., Heffernan M.E. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm (Lond) 2008, 5:10-18.
66. Michos E.D., et al. Serum 25-hydroxyvitamin d levels are not associated with subclinical vascular disease or C-reactive protein in the old order amish. Calcified Tissue Int 2009, 84(3):195-202.
67. Oelzner P., et al. Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford) 1999, 38(9):841-847.
68. Gannage-Yared M.H., et al. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Invest 2003, 26(8):748-753.
69. Vilarrasa N., et al. Is plasma 25(OH) D related to adipokines, inflammatory cytokines and insulin resistance in both a healthy and morbidly obese population?. Endocrine 2010, 38(2):235-242.
70. Shea M.K., et al. Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham offspring study. Am J Epidemiol 2008, 167(3):313-320.
71. Schleithoff S.S., et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006, 83(4):754-759.
72. Zittermann A., et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009, 89(5):1321-1327.
73. Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate?. J Steroid Biochem 2004, 89-90(1-5):611-614.
74. Dawson Hughes B., et al. Estimates of optimal vitamin D status. Osteoporos Int 2005, 16(7):713-716.